Xconomy: Inspyr, Formerly GenSpera, Replaces Co-Founder Dionne With New CEO
Summary
Inspyr, Formerly GenSpera, Replaces Co-Founder Dionne With New CEO Xconomy Texas — San Antonio—Inspyr Therapeutics, a biotech company based in San Antonio formerly known as GenSpera, has hired Christopher Lowe as its new CEO and president, replacing co-founder Craig Dionne after he abruptly left the company in March.FLG calls itself a CFO-as-a-service business, primarily providing the advice, mentorship, and leadership to companies that a chief financial officer would.Dionne spoke to Xconomy a month before his departure, discussing the company’s efforts to fund ongoing Phase 2 trials into its lead candidate, mipsagargin or G-202, for glioblastoma multiforme, a fast-growing brain tumor.You can read more from that conversation here, and more about the company’s background in this 2014 profile by Xconomy’s Bernadette Tansey.The therapy is based in a toxin, thapsigargin, which is found in a weed called Thapsia Garganica.
Classifications
AskAI Classifications
LabelsLinked Companies
